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Dear Editor, 7 
I would like to thank referees for their careful reading of our manuscript and for their remarks, 8 
which were very helpful to us. We have improved the manuscript according of reviewers' 9 
comments. We hope that the revised version of our paper, enclosed herein, properly fulfils all 10 
the recommendations. 11 
First of all, we re-worked the part of the results and the discussion in the following 12 
manner: 13 
• we begun this section with an overview of our previous study involving the reaction of 14 
dinitrostilbene derivatives with sodium azide, 15 
• we  included a scheme 2 outlining the transformation key intermediates, 16 
• we used our previous work to introduce our hypothesis for the new work, 17 
• we discussed the olefin isomerisation, and proposed role of azide in this reaction,  18 
• we referred the calculations performed in DMSO, because the reaction proceeded in 19 
DMSO, and also NMR was measured in DMSO-d6. The structures were investigated 20 
in DMSO. In the text we supplemented the information on the type of solvent, 21 
• we summarized the methods of preparation of dibenzo[b, f]oxepine in figure 2, 22 
• we corrected the NMR analysis of compounds and references according to the 23 
template of Tetrahedron, 24 
• we did not  include the mass (only mmol) in part of General procedure of synthesis of 25 
dibenzo[b,f]oxepines, because the same procedure applied for all products, 26 
  27 
 28 
----------------------------------- 29 
 30 
We hope that the new revised version of our manuscript is now suitable for publication in the 31 
Tetrahedron. 32 
Yours sincerely, 33 
Hanna Krawczyk 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
Synthesis of derivatives of methoxydibenzo[b, f]oxepine in  the presence of sodium azide 1 
 2 
Hanna Krawczyk, a* Michał Wrzesiński,b  Damian Mielecki, b Przemysław Szczeciński,a  3 
and Elżbieta Grzesiuk,b 4 
aDepartment of Organic Chemistry, Faculty of Chemistry Warsaw University of Technology, 5 
Noakowskiego 3,00-664 Warsaw, Poland; bInstitute of Biochemistry and Biophysics Polish 6 
Academy of Sciences, Pawińskiego 5a, 02-106 Warsaw, Poland  7 
 8 
Corresponding Author 9 
* Hanna Krawczyk, Department of Organic Chemistry, Faculty of Chemistry Warsaw 10 
University of Technology, Noakowskiego 3,00-664 Warsaw, Poland; 11 
Fax: +48 22 628 27 41;  E-mail address: hkraw@ch.pw.edu.pl  12 
 13 
Keywords: cyclization • methoxydibenzo[b, f]oxepines •heterocycles• DFT calculations• 14 
molecular modeling 15 
 16 
Abstract:  17 
Dibenzo[b,f]oxepin is an important scaffold in medicinal chemistry and its derivatives occur 18 
in several medicinally important plants. A new approach to methoxydibenzo[b, f]oxepines 19 
(15-21) proceeding under mild reaction conditions, has been developed. Notably, the use of 20 
sodium azide in reaction allow obtaining the new substituted dibenzo[b, f]oxepines. In order 21 
to study their shape and conformation, the optimum structures of the compounds were 22 
calculated using the DFT B3LYP/6-311++G(2d, p) method. A docking simulation was 23 
performed to insert compound 20  into the crystal structure of tubulin at the colchicine 24 
binding site to determine the probable binding model. The information of this work can be 25 
helpful for the investigation of new tubulin polymerization inhibitors exhibiting stronger 1 
activity. 2 
Introduction 3 
The growth and development of most solid tumors require that they form their own functional 4 
vascular supply, which is produced from the host’s normal vascular network in the process of 5 
angiogenesis. This neo-vasculature of tumors is, due to its significance, an excellent target in 6 
terms of annihilating cancer cells. Two forms of vascular targeting agents (VTAs) have 7 
evolved: those that inhibit the angiogenesis process (called angiogenesis inhibitors, AIs) and 8 
those that damage the already-established vessels (vascular disrupting agents, VDAs).1,2 9 
Combretastatins CA1P (OXi4503) and CA4P (a class of naturally occurring stilbene 10 
derivatives, Fig. 1) are new vascular disrupting agents and vascular targeting agents.1,2 They 11 
exhibit remarkable abilities to inhibit gastric tumor metastasis and to enhance antitumor 12 
immune reactivity.3  OXi4503 is the diphosphate prodrug of the stilbenoid combretastatin A1, 13 
originally isolated from the plant Combretum caffrum, with vascular-disrupting and 14 
antineoplastic activities.4-7 Upon administration, combretastatin A1 diphosphate (CA1P) is 15 
dephosphorylated to afford the active metabolite combretastatin A1 (CA1), which promotes 16 
rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis, destruction 17 
of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis may ensue.8-18 
10
 The corresponding disodium phosphate prodrug of CA-4 (fosbretabulin, Fig.1) is currently 19 
of an advanced stage of clinical development, having recently entered phase II/III studies in 20 
combination with carboplatin or paclitaxel in patients with anaplastic thyroid cancer.11-13 It is 21 
worth noting that these compounds contain numerous methoxy groups in the framework. 22 
Moreover, only the Z-isomer of the stilbenoid exhibits the properties of a drug, whereas the E-23 
isomer does not.14 24 
 25 
 26 
 1 
Figure 1. The structure of CA1P, CA4P and their sodium salts -OXi4503 and fosbretabulin, 2 
and structure of colchicine. 3 
 4 
Continuing our study concerning the synthesis and search for biologically active 5 
stilbenes,15-20 we have directed our attention to the dibenzo[b,f]oxepines. These compounds 6 
have in their skeleton a (Z)- stilbene motif, and additionally their aromatic rings are connected 7 
by the oxygen. Moreover, dibenzo[b,f]oxepin is an important scaffold in medicinal chemistry 8 
and its derivatives occur in several medicinally important plants.21-26 Molecules with this 9 
skeleton exhibit antidepressive,27,28 antipsychotic,29-34 anti-estrogenic,35 antitumor25 and anti-10 
inflammatory36 properties. Their activity as VTAs has not been investigated. 11 
Multiple synthetic pathways provide access to the dibenzo[b,f]oxepin scaffold 12 
(Fig.2).27-60  One of these has focused primarily on the combination of Ullmann coupling and 13 
the Friedel-Crafts reaction.27,28,32,36-38 An efficient synthesis is a two-step protocol that 14 
involves Ullmann coupling and ring-closing metathesis reactions.28 Also the nucleophilic 15 
aromatic substitution reaction (SNAr) has been often used for the formation of biaryl ethers.39-16 
43
 Expansion of a xanthene ring using a Wagner-Meerwein rearrangement or, a Mn (III)- 17 
based oxidative radical rearrangement has been an interesting method, too.44-49 In the 18 
synthesis of dibenzo[b,f]oxepines a sequential Heck reaction and Pd-catalyzed etherification 19 
were adopted.50,51 20 
 21 
 1 
 2 
Figure 2. Examples of methods for the preparation of the dibenzo[b,f]oxepin scaffold: a) the 3 
combination of Ullmann coupling and the Friedel-Crafts reaction;27,28,32, 36-38  b) the Ullmann 4 
coupling and ring-closing metathesis reactions;28 c) the Wagner-Meerwein rearrangement; 44-5 
47  d) one-pot transition-metal-free synthesis from 2-halobenzaldehydes.52 6 
 7 
Another noteworthy approach has been to prepare dibenzo[b,f]oxepines with various 8 
functional groups via a one-pot cascade reaction53 under Cu-assisted as well as Cu-free 9 
conditions.52 Synthetic approaches to naturally occurring dibenzo[b,f]oxepins concerned 10 
mainly the preparation of various bauhinoxepins.54-58  In 2001, Chernysheva et al.59,60 11 
reported a one-pot procedure to prepare NO2-substituted dibenz[b,f]oxepines. However, this 12 
method involved explosive 2,4,6-trinitrotoluene as the starting reagent. 13 
As part of a program to search for biologically active stilbenes we have sought to 14 
develop an efficient and easy synthesis of methoxydibenzo[b,f]oxepines. 15 
  16 
 17 
Results and Discussion 18 
 In our previous study we found that the reaction between a derivative of 2,4-19 
dinitrostilbene and sodium azide always gave the corresponding (E)-2-amino-4-nitrostilbene 20 
as the sole product (Scheme 1).15-20 The reaction was regiospecific with only the ortho-NO2 21 
group replaced. We have shown that the transformation proceeds via an intermediate azide 22 
product which after about 1 h gradually disappears with simultaneous formation of the final 1 
amine product.16-20 On the basis of our investigations, we hypothesize that the strongly 2 
electron-withdrawing nitro group at position 4 in the substrates makes the nitro group at 3 
position 2 more prone to substitution by the azide group and subsequently to reduction into an 4 
amine group. Because the ortho-nitro group is  more prone to substitution we suppose that 2-5 
hydroxy-2',4'- dinitrostilbenes can undergo intramolecular nucleophilic substitution and can 6 
finally give dibenzo[b,f]oxepines scaffold. 7 
 8 
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Scheme 1. The unanticipated formation of aminostilbenes 1b-7b from nitrostilbenes 1a-7a 10 
under azidation conditions. 11 
Herein, we report a two-step synthesis of dibenzo[b,f]oxepin that involves the 12 
condensation of 2,4-dinitrotoluene with various substituted methoxyaldehydes61 and 13 
subsequent cyclization of the obtained stilbenes. The cyclization reactions were made both  14 
without and with sodium azide, to assess if azide was formed before there was isomerization 15 
to form Z and cyclization to dibenzo[b,f]oxepin. Serendipitously, the addition of sodium azide 16 
influenced the yield of these reactions. In our investigation we conducted studies of the 17 
cyclization reaction of (E)-2-hydroxy-2',4'-dinitrostilbene (8) and the methoxy derivatives of 18 
(E)-2-hydroxy-2',4'-dinitrostilbene (9-13) and the nitro derivative of (E)-2-hydroxy-2',4'-1 
dinitrostilbene (14) in the presence of sodium azide (Table 1). In all cases we obtained the 2 
scaffold of dibenzo[b,f]oxepine (15-21). Just like with the derivatives of 2,4-dinitrostilbene 3 
without a hydroxyl group, only the ortho-NO2 group in position 2’ was replaced. We can 4 
assume that a stilbene substituted with two electron-withdrawing NO2 groups located in one 5 
of the rings, reduces the electron density in the system. As a result, nucleophilic substitution 6 
of one of the nitro groups by the hydroxyl oxygen from the 2-position derived from the other 7 
aryl ring is possible. In the case of derivative (E)-2-hydroxy-2',4'-dinitrostilbenes, the azide 8 
intermediate products have not been observed.  9 
 10 
Table 1. Synthesis of dibenzo[b,f]oxepines (15-21). 11 
 12 
 13 
 14 
Compound 
number 
R1 R2 R3 R4 yield (%)a 
8,15 H H H H 92 
9,16 OCH3 H H H 88 
10,17 H OCH3 H H 95 
11,18 H H OCH3 H 95 
12,19 H H H OCH3 95 
13,20 OCH3 H OCH3 H 95 
14,21 NO2 H H H 90 
a  Isolated yield. 
 15 
During our examination we have investigated reaction formation of 1 
dibenzo[b,f]oxepines without sodium azide. We observed far lower yield in products (15-20) 2 
and, surprisingly, the absence of 21. The relative rates were about 50% higher for reactions 3 
with sodium azide than the reactions without sodium azide. We concluded that to get high 4 
yield of oxepines there should be sodium azide. 5 
In order to explain the selectivity of cyclization we calculated energy minima of the 6 
reactants in DMSO solution. The optimum structure of 8-14 using the DFT B3LYP/6-7 
311++G(2d, p) method was calculated (see Supplementary Information). It appeared that the 8 
ortho-nitro group of 2’ was rotated around the C–N axis by 30.8o and 36.9o for (8-14) (Table 9 
2) and that the para-nitro group was coplanar with respect to the aromatic ring (see 10 
Supplementary Information). On the basis of our calculations, we have hypothesized that the 11 
coupling of p electrons of the nitro group from position 2’ with pi electrons in the aromatic 12 
ring is less effective than in the case of the nitro group at position 4’ and makes the nitro 13 
group at position 2’ more prone to substitution. 14 
Table 2. The calculation angles between the ortho-nitro group in position 2 and ring of 8-14 15 
stilbenes.  16 
 17 
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 24 
The DSC analysis of cyclization reaction of compound 9 with and without azide has 25 
been done and is presented in Fig.3 ( in this process the product 16  was obtained). The DSC 26 
 
 
Compound           Angles (o)  
8  36.4 / 34.9 
9 
10 
31.6 / 31.5 
34.1 / 34.4 
11 31.4 / 31.4 
12 30.8 / 30.8 
13 31.3 / 31.3 
14 33.7 / 34 
  
analysis provides information on the transformation of an analyte, which depends on the heat 1 
exchange conditions in the analyzer–sample system (see Supplementary Information). 2 
Measurements were taken at 0.1 oC/min heating rate. The analysis showed only one 3 
exothermic transition above 88 oC in cyclization with azide and above 98 oC in the reaction 4 
without azide. Based on Ozawa–Flynn–Wall analysis, conversion vs. the activation energy 5 
were estimated. It could be observed that, e.g. for 0.1 conversion, the activation energy in 6 
cyclization with azide was lower than without azide (about 6.59 kJ/mol, see Supplementary 7 
Information). Therefore, one can conclude that the sodium azide decreases the activation 8 
energy of cyclization reaction and, probably for compound 14, allows the reaction to proceed. 9 
The results of calculations show the para-nitro substituent aligning in conjugation 10 
with the benzene ring whilst the ortho-nitro substituent twists out of conjugation, presumably 11 
for steric reasons. The coplanarity of the para-nitro group may be important for an 12 
intramolecular SNAr mechanism. We have hypothesized that the phenoxide attacks the 13 
electron-deficient ring to form a spiro intermediate, which then undergoes ring expansion 14 
with expulsion of a leaving group (Table 1).  The process proceeds for all stilbenes (8-13) but 15 
only in the case 14 (phenoxide ring is bonded with EWG group) with sodium azide. The 16 
addition of sodium azide could influence the process of isomerization of stilbenes from E to 17 
Z, because the relative rates were about 50% higher for reactions with sodium azide than for 18 
the reactions without sodium azide (15-20) (the azide intermediate products have not been 19 
observed). In the literature there are examples of compounds investigated as E/Z catalysts of 20 
stilbene.62 NO was tested as an E/Z catalyst of stilbene in solution.62 However, C=C bonded 21 
molecule investigated showed slight increase in the rate of isomerization, but the experiment 22 
was performed at room temperature. The E/Z isomerization of stilbene in the presence of 23 
NaN3 has not been previously described. 24 
 25 
Figure 3. DSC curves of the cyclization of compound 9 with (-) and without azide (-). 1 
 2 
In order to determine the structure of reaction products (15-21) in solution, 1H and 13C 3 
NMR spectra of all the products have been measured (complete data shown in Supplementary 4 
Information). The 1H and 13C NMR resonances were assigned unequivocally, based on the 5 
combined information from 1D to 2D NMR (gCOSY, gHSQC and gHMBC) experiments. 6 
Coupling constants (1H–1H) were measured directly from resolution-enhanced 1D spectra and 7 
confirmed, when necessary, by homo-decoupling. gHSQC and gHMBC analysis allowed the 8 
assignment of the dibenzo[b,f]oxepines regiochemistry. 9 
Additionally, the optimum structure of 15-21 was calculated using the DFT B3LYP/6-10 
311++G(2d,p) method (and with polarizable continuum model–PCM) [see Supplementary 11 
Information]. Calculations have shown that the scaffold of dibenzo[b,f]oxepine is not planar 12 
and that it creates a basket. The dihedral angles between aromatic rings connected with 13 
oxygen and double bound for 15-21 dibenzooxepines are 64.9o-68.8o (Table 3). 14 
As we previously mentioned, upon administration, combretastatin A1 diphosphate 1 
(CA1P) is dephosphorylated to the active metabolite combretastatin A1 (CA1) (Fig.1), which 2 
promotes rapid microtubule depolymerization.63-66 Microtubules are highly dynamic polymers 3 
and their essential element is the α/β-tubulin heterodimer. The tubulin heterodimer contains at 4 
least three distinct drug binding sites: the paclitaxel, vinblastine, and colchicine binding sites. 5 
67
 For the first two of these sites, drugs are in current use in clinical oncology.68 Over the last 6 
decades, a large number of compounds able to interact with the colchicines binding site have 7 
been investigated.69 However, no colchicine site inhibitor has found clinical application in 8 
anticancer therapy. Colchicine (Fig.1) itself binds to tubulin very tightly, but its severe 9 
toxicity to normal tissues has hampered its use in the clinic.70 Colchicine is known to bind the 10 
non-polymerized tubulin.70 The C ring of colchicine interacts establishing van der Waals 11 
contacts with Valα181, Serα178, and Valβ315. The carbonyl group behaves as a hydrogen 12 
bond acceptor, interacting with Valα181. The A ring is buried in a hydrophobic pocket 13 
delimited by Lysβ352, Asnβ350, Leuβ378, Alaβ316, Leuβ255, Lysβ254, Alaβ250 and 14 
Leuβ242, and the methoxy group at position 3 is involved in a hydrogen bond interaction 15 
within the thiol group of Cysβ241. Currently, combretastatin A-4 (CA-4) is one of the most 16 
promising anti-tubulin agents that targets the colchicines site.71 17 
Consequently, the ability of compound 20, which is structurally the closest to 18 
combretastatin A1, to interact with the tubulin (crystal structure from PDB code: 1SA0)72 has 19 
been analyzed by computer molecular modeling. The molecular docking was performed by 20 
simulation of compound 20 into the colchicine binding site in tubulin All docking runs were 21 
applied the Broyden-Fletcher-Goldfarb-Shanno (BFGS) method of AutoDock Vina 22 
program.73,74 23 
 24 
 25 
 26 
 27 
 28 
Table 3. The calculation dihedral angles aromatic rings connected with oxygen and double 1 
bound for 15-21. 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
The binding model of compoundnd tubulin is depicted in Figure 4. The amino acid 13 
residue of α and β tubulin (crystal structure from PDB code: 1SA0)72 was labeled. In the 14 
binding mode, compound   	
   	 	
	   	  hydrophobic 15 
interaction and binding  
  a hydrogen bond. The nitro group behaves as a 16 
hydrogen bond acceptor, interacting with Valα181. The calculated binding	were used 17 
asparameters for the selection of the cluster of docking posed to be evaluated (Fig.4a,b), in 18 
which the binding mode of the lowest energy structure was located (selection of the cluster in 19 
docking for the lowest energy structure (pose) of investigated molecule). Theselected pose of20 
 had an estimated binding free energy of   (binding free energy of control 21 
compounds colchicine and CA-4 are -8.6 kcal/mol and -7.62 kcal/mol, respectively71) 22 
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Compound Angles (o) 
15 66.1 / 66.9 
16 67.6 /68.2 
17 64.9 / 66.8 
18 66.7 /66.5 
19 66.1 /68.8 
20 68.4 / 68.6 
21 66.7 /66.3 
a) 
b) 
 1 
Figure 4. a) 3D model of the interaction between compound 20 and the colchicine binding 2 
site of α and   β   tubulin  (crystal structure from PDB code: 1SA0);72 b) the selected pose of  3 
20 -an estimated binding free energy of -7.2 kcal/mol. 5 
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Conclusions 47 
In summary, we have developed a new, easy synthesisdibenzo[b,f]oxepine from substituted 48 
2-hydroxy-2',4'-dinitrostilbene with high yield. Notably, the addition of sodium azide 49 
decreases the activation energy in a cyclization reaction and, therefore, the cyclization 1 
reaction with EWG group in the ring may be performed. Calculations show that the scaffold 2 
of dibenzo[b,f]oxepine is not planar and that it creates a basket, which may be significant in 3 
further application of this method for the synthesis of medicinally useful compounds. 4 
Molecular docking was further performed to study '	
	
 tubulin protein interactions. 5 
After analysis of the binding model of compound 20 with tubulin, it was found that several 6 
interactions with the protein residues in the colchicine binding site are present. This 7 
information can be helpful for the investigation of new  tubulin polymerization inhibitors 8 
exhibiting stronger activitiy. The biological activity of our products (15-21) will be 9 
investigated in the near future.  10 
Materials and methods 11 
All the spectra were recorded using a Varian VNMRS spectrometer operating at 11.7 T 12 
magnetic field. Measurements were performed for ca. 1.0 M solutions of all the compounds in 13 
DMSO-d6.  The residual signals of DMSO-d6 (2.54 ppm) in 1H NMR and the  DMSO-d6 14 
signal (40.45 ppm) in 13C NMR spectra were used as the chemical shift references. All the 15 
proton spectra were recorded using the standard spectrometer software and parameters set: 16 
acquisition time 3 s, pulse angle 300. The standard measurement parameter set for 13C NMR 17 
spectra was: pulse width 7 µs (the 90 o pulse width was 12.5 µs), acquisition time 1 s, spectral 18 
width 200 ppm, 1000 scans of 32 K data point were accumulated and after zero-filling to 64 19 
K; and the FID signals were subjected to Fourier transformation after applying a 1 Hz line 20 
broadening. The 1H–13Cgs-HSQC and 1H–13Cgs-HMBC spectra were also recorded using the 21 
standard Varian software. All (E)-2’-hydroxy-2,4-dinitrostilbenes used in 22 
dibenzo[b,f]oxepines synthesis were obtained according H. Hoyer, M. Vogel procedure. 61 23 
General procedure of synthesis of dibenzo[b,f]oxepines 15-21 (Table 1): (E)-2’-Hydroxy-24 
2,4-dinitrostilbene (1.70 mmol), and NaN3 (190 mg, 2.95 mmol) in DMSO (15 ml), were 25 
sequentially added to a three-necked flask (25 mL) fitted with a condenser. The mixture was 26 
stirred at 120 0C for 24 h and concentrated in vacuo (see Supplementary Information). The 1 
residue was purified by flash column chromatography on silica gel (toluene → toluene: 2 
MeOH, 9:1).  3 
IR spectra 4 
The IR spectra were recorded at ambient temperature on a Perkin Elmer System 2000, using 5 
the technique of Attenuated Total Reflectance (ATR) for compounds (15) and (16). Other 6 
compounds (17-21) were recorded on a FTIR Nicolet 6700  using ATR (see Supplementary 7 
Information). 8 
Computational aspects  9 
The optimum ground-state geometry for compounds (8-21)  were calculated using density 10 
functional theory (DFT). 77  The B3LYP functional and 6-311G 6-311++g (2d,p) basis set and 11 
the continuum model (PCM; Gaussian 03W) 78 was used in order to simulate the effects of the 12 
solvent -DMSO. All the calculations were performed on a server equipped with a 16 quad-13 
core XEON (R) CPU E7310 processor operating at 1.60 GHz. The operating system was 14 
Open SUSE 10.3. (see Supplementary Information). Molecular docking of compound 13 into 15 
the 3D X-ray structure of tubulin (PDB code: 1SA0)72 was carried out using the Auto-Dock 16 
Vina software (the Broyden-Fletcher-Goldfarb-Shanno (BFGS) method)73  Configurations of 17 
protein/ dimethoxydibenzo[b, f]oxepine complex was created using UCSF Chimerasoftware.74 18 
The graphical user interface ADT was employed to set up the enzyme: all hydrogens were 19 
added. For macromolecules, generated pdbqt files were saved. The 3D structures of ligand 20 
molecules were built, optimized (B3LYP functional and 6-311G 6-311++g (2d,p) basis set) 21 
level, and saved in Mol2 format. The graphical user interface ADT was employed to set up 22 
also the ligand and pdbqt file was saved. Auto-Dock Vina software was employed for all 23 
docking calculations. The AutoDockTools program was used to generate the docking input 24 
files. In docking a grid box size of 44x46x44 points in x, y, and z directions was built, the 25 
maps were center located (115.574, 89.495, 7.664) in the catalytic site of the protein. A grid 26 
spacing of 0.375 Å (approximately one forth of the length of carbon-carbon covalent bond) 1 
was used for the calculation of the energetic map.  2 
 3 
Analysis of compounds (15-21): 4 
3-nitrodibenzo[b,f]oxepine- (15): stirred at 120 0C for 24 h, yield 92% (373 mg; 1.56 mmol), 5 
dark yellow powder, mp 150.0-150.2 0C; 1H NMR (500 MHz, DMSO-d6, 25 °C): δ = 2,54 6 
(quintet, 6H, (Me3)2): 8.15 (d, 3JH,H =2.5 Hz, 1H, 4-H), 8.09 (dd, 3JH,H =8.5 Hz, 3JH,H =2.5  7 
Hz, 1H, 2-H); 7.62 (d, 3JH,H =8.5, 1H, 1-H), 7.48 (ddd, 3JH,H =7.5, 3JH,H = 7.5 Hz, 3JH,H = 1.5 8 
Hz, 1H,7-H), 7.45(dd, 3JH,H =7.5, 3JH,H = 1.5 Hz, 1H, 6-H), 7.41(dd, 3JH,H = 7.5, 3JH,H =1.5 Hz, 9 
1H, 9-H), 7.28 (ddd, 3JH,H =7.5, 3JH,H = 7.5 Hz, 3JH,H = 1.5 Hz, 1H, 8-H), 7.08 (d (spin system 10 
AB), 3J H,H=11.5 Hz,  1H,10-H ), 6.98 (d (spin system AB), 3J H,H=11.5 Hz,  1H, 11-H). 13C 11 
NMR (125 MHz, DMSO-d6, 25°C): δ= 156.93 (C-13), 156.86 (C-14), 149.05(C-3), 138.01 12 
(C-12), 134.36(C-10), 132.06 (C-7), 131.12 (C-1), 130.80 (C-9), 130.43 (C-15), 129.10 (C-13 
11), 126.73(C-8), 122.35 (C-6), 121.26 (C-2), 117.46 (C-4), 40.45 (C-DMSO-d6) ppm.  14 
HRMS (EI+ 3.19e3): m/z calculated for C14H9NO3 239.0582; found 239.0583. 15 
6-methoxy-3-nitrodibenzo[b,f]oxepine (16): stirred at 120 0C for 24 h, yield 88% (404 mg; 16 
1.50 mmol), yellow powder, mp 180.0-180.3 0C; 1H NMR (500 MHz, DMSO-d6, 25°C):δ = 17 
2,54 (quintet, 6H, (Me3)2), 8.09 (d, 3JH,H = 8.5 Hz, 1H, 2-H), 7.94 (d, 3JH,H = 2.5 Hz, 1H, 4-H), 18 
7.64 ( d, 3JH,H = 8.5, 1H, 1-H), 7.22 (d, 3JH,H =3 Hz, 1H,7-H), 7.21 (d, 3JH,H =6 Hz, 1H, 9-H), 19 
7.09 (d (spin system AB), 3J H,H= 11.5 Hz, 1H, 10-H), 7.01 (d, 3JH,H =11.5 Hz, 1H, 11-H), 20 
6.96 (dd, 3JH,H =6 Hz, 3JH,H =3Hz, 1H, 8-H), 3.95 (3H, OCH3) ppm. 13C NMR (125 MHz, 21 
DMSO-d6, 25°C): δ= 156.73 (C-13), 152.26 (C-6), 148.86(C-3), 144.46(C-14), 138.31(C-12), 22 
134.39(C10), 131.54(C-15),  131.07(C-1), 129.19 (C-11), 126.81(C-9),  121.75(C-8), 121.28 23 
(C-2), 117.19 (C-4), 114.98 (C-7), 57.12 (OCH3) 40.45(C-DMSO-d6) ppm. HRMS (ESI TOF, 24 
MeOH): m/z calculated for C15H11NO4Na (M++Na) 292.0586; found 292.0576. 25 
3-methoxy-7-nitrodibenzo[b,f]oxepine (17): stirred at 120 0C for 24 h, yield 95% (436 mg; 1 
1.62 mmol), dark brown powder, mp 174.9-175.3 0C; 1H NMR (500 MHz, DMSO-d6, 2 
25°C): δ = 2,54 (quintet, 6H, (Me3)2), 8.17 (d, 3JH,H = 2.0 Hz, 1H, 6-H), 8.08 (dd, 3JH,H = 9.0 3 
Hz, 3JH,H =2.0 Hz, 1H, 8-H), 7.57 (d, 3JH,H = 9.0 Hz, 1H, 9-H), 7.31 (d,  3JH,H = 8.5 Hz, 1H, 1-4 
H), 7.11 (d, 3JH,H = 2.5 Hz, 1H, 4-H), 6.99 (d (spin system AB), 3J H,H= 11.5 Hz, 1H, 11-H), 5 
6.86 (dd, 3JH,H =8.5, Hz , 3JH,H =2.5 Hz, 1H, 2-H), 6.81(d (spin system AB), 3J H,H= 11.5 Hz, 6 
1H, 10-H), 3.84 (s, 3H,OCH3) ppm. 13C (125 MHz, DMSO-d6, 25°C): δ =163.03 (C-3), 7 
157.95 (C-13), 156.27(C-14), 148.76(C-7), 138.55(C-15),134.28(C-11), 131,62 (C-1), 8 
130.85(C-9), 126.61(C-10), 123.09(C-12), 121.33(C-8), 117.69 (C-6), 112.80(C-2), 108.01 9 
(C-4), 56.60 (OCH3), 40.45(C-DMSO-d6) ppm. HRMS (EI+ 5.98e3): m/z calculated for 10 
C15H11NO4 269.0688; found 269.0687. 11 
2-methoxy-7-nitrodibenzo[b,f]oxepine (18): stirred at 120 0C for 24 h, yield 95% (436 mg; 12 
1.62 mmol), bright brown powder, mp 176.0-176.4 0C; 1H NMR (500 MHz, DMSO-d6, 13 
25°C): δ = 2,54 (quintet, 6H, (Me3)3), 8.13 (d, 3JH,H =2.5 Hz, 1H, 6-H), 8.08 (dd, 3JH,H =8.5 14 
Hz, 3JH,H =2.5, 1H, 8-H), 7.61 (d, 3JH,H =8.5 Hz, 1H, 9-H), 7.37 (d, 3JH,H =9.0 Hz, 1H, 4-H), 15 
7.04 (d (spin system AB), 3J H,H= 11.5Hz, 1H, 11-H), 7.02 (dd, 3JH,H =9.0 Hz, 3JH,H =3.0 Hz, 16 
1H, 3-H), 6.98 (d (spin system AB), 3J H,H= 11.5Hz, 1H, 10-H), 6.97 (d, 3JH,H =3.0 Hz, 1H, 1-17 
H), 3.78(s, 3H, OCH3) ppm. 13C (125 MHz, DMSO-d6, 25°C): δ = 157.57 (C-2), 157.28 (C-18 
14), 150.52 (C-13),  149.06 (C-7), 137.98 (C-15),134.30 (C-11), 131,20 (C-9), 131.12(C-12), 19 
129.42(C-10), 123.08(C-4), 121.13(C-8), 117.28 (C-6), 117.19(C-3), 114.96 (C-1), 56.50 20 
(OCH3), 40.45(C-DMSO-d6) ppm. HRMS (EI+ 1.09e4): m/z calculated for C15H11NO4  21 
269.0688; found 269.0691. 22 
1-methoxy-7-nitrodibenzo[b,f]oxepine (19): stirred at 120 0C for 24 h, yield 95% (436 mg; 23 
1.62 mmol), bright brown powder, mp 141.8-142.0 0C; 1H NMR (500 MHz, DMSO-d6, 24 
25°C): δ = 2,54 (quintet, 6H, (Me3)2), 8.14 (d, 3J H,H =2.5 Hz, 1H, 6-H), 8.09 (dd, 3J H,H =8.5 25 
Hz, 3J H,H=2.5 Hz, 1H, 8-H), 7.60 (d, 3JH,H=8.5, 1H, 9-H), 7.45 (dd, 3JH,H =8.5 Hz, 3J H,H =8.0 1 
Hz, 1H, 3-H), 7.19 (d (spin system AB), 3J H,H= 11.5Hz, 1H, 11-H), 7.06 (d, 3JH,H =8.0 Hz, 2 
1H, 4-H), 6.98 (d (spin system AB), 3JH,H= 11.5Hz, 1H, 10-H), 6.96 (d, 3JH,H =8.5 Hz, 1H, 2-3 
H), 3.87 (s, 3H, OCH3) ppm. 13C (125 MHz, DMSO-d6, 25°C): δ = 158.58 (C-13), 157.98 (C-4 
1), 156.97(C-14), 149.00(C-7), 138.59(C-15), 132.57(C-3), 130,87 (C-9) 128.95(C-11), 5 
128.37(C-10), 121.38(C-8), 119.17(C-12), 117.49 (C-6), 114.46 (C-4), 109.36 (C-2), 57.12 6 
(OCH3), 40.45 (C-DMSO-d6) ppm. HRMS (EI+1.36e4): m/z calculated for C15H11NO4 7 
269.0688; found 269.0690. 8 
2,4-dimethoxy-7-nitrodibenzo[b,f]oxepine (20): stirred at 120 0C for 24 h, yield 95% (484 9 
mg; 1.62 mmol), bright brown powder, mp 139.1-139.4 0C; 1H NMR (500 MHz, DMSO-d6, 10 
25°C): δ = 2,54 (quintet, 6H, (Me3)2), 8.09 (dd, 3J H,H =8.5 Hz, 3J H,H =2.5 Hz, 1H, 8-H), 7.90 11 
(d, 3J H,H =2.5Hz, 1H, 6-H), 7.64 (d, 3JH,H =8.5 Hz, 1H, 9-H), 7.05 (d (spin system AB), 3J 12 
H,H= 11.5Hz, 1H, 11-H), 7.02(d (spin system AB), 3J H,H= 11.5Hz, 1H, 10-H), 6.78 (d, 3J H,H 13 
=2.5 Hz, 1H, 3-H), 6.54 (d, 3J H,H = 2.5 Hz, 1H, 1-H), 3.93 (s, 3H, OCH3), 3.78 (s, 3H, OCH3) 14 
ppm. 13C (125 MHz, DMSO-d6, 25°C): δ= 157.73 (C-2), 157.06 (C-14), 152.77 (C-4), 148.84 15 
(C-7), 138.55 (C-13), 138.27 (C-15), 134.51 (C-11), 131.55 (C-12), 131.11 (C-9),  129.46 (C-16 
10), 121.12 (C-8), 116.97 (C-6), 104.85(C-1), 102.36 (C-3), 57.19 (OCH3), 56.51 (OCH3), 17 
40.45 (C-DMSO-d6) ppm. HRMS (EI+ 3.80e3): m/z calculated for C16H13NO5 299.0794; 18 
found 299.0792. 19 
3,6-dinitrodibenzo[b,f]oxepine (21): stirred at 120 0C for 24 h, yield 90% (435 mg; 1.53 20 
mmol), brown powder above 149.8-150.1 0C the decomposition. 1H NMR (500 MHz, DMSO-21 
d6, 25°C): δ = 2,54 (quintet, 6H, (Me3)2), 8.20 (dd, 3J H,H =8.5 Hz, 3J H,H =2.5 Hz, 1H, 2-H), 22 
8.06 (d, 3J H,H= 2.5 Hz, 1H, 4-H), 8.05 (dd, 3J H,H= 8.0 Hz, 3J H,H= 1.5 Hz,  1H, 7-H), 7.77 (dd, 23 
3J H,H= 8.0 Hz, 3J H,H= 1.5 Hz, 1H, 9-H), 7.72 (d, 3J H,H=8.5 Hz, 1H, 1-H), 7.51 (t, 3J H,H= 8.0 24 
Hz, 1H, 8-H), 7.18 (d (spin system AB), 3J H,H= 11.5Hz, 1H, 11-H), 7.14 (d (spin system AB), 25 
3J H,H= 11.5Hz, 1H, 10-H) ppm. 13C (125 MHz, DMSO-d6, 25°C): δ =155.99(C-13), 149.28 1 
(C-3), 147.33 (C-6), 143.93 (C-14), 137.37 (C-12), 135.43 (C-9), 133.02(C-11), 131.83 (C-1),  2 
131.06 (C-10), 127.39 (C-8), 126.43 (C-7), 122.31(C-2), 117.37(C-4), 115.41 (C-15), 40.45 3 
(C-DMSO-d6) ppm. HRMS  (EI+ 1.87e4): m/z calculated for C14H8N2O5 284.0433; found 4 
284.0439. 5 
The analysis DSC of (9) were carried out with DSC Q2000 TA Instruments. 6 
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